Alterity Therapeutics Ltd ATHE Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.22 down $0.22, 9.02% at close Nov 5
Last close · Previous close $2.44
- Market cap
- At the Nov 5 close
- Dividend yield
- NoneLast 12 months
Price chart
$2.22down $0.22, 9.02%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.44Nov 4
- Volume40.34KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume223.49KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.01 to $5.89; now $2.22
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ATHE trailed the S&P 500 in all 7 periods.
| Period | ATHE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATHE: down 31.1% S&P 500: down 5.4% | ATHE trailed the S&P 500 by 25.7 percentage points Trailed |
| 3M | ATHE: down 49.2% S&P 500: down 4.5% | ATHE trailed the S&P 500 by 44.7 percentage points Trailed |
| YTD | ATHE: down 27.9% S&P 500: up 8.3% | ATHE trailed the S&P 500 by 36.2 percentage points Trailed |
| 1Y | ATHE: down 43.1% S&P 500: up 9.3% | ATHE trailed the S&P 500 by 52.4 percentage points Trailed |
| Long term | ||
| 3Y | ATHE: down 7.5% S&P 500: up 74.8% −2.6% vs +20.5% a year | ATHE trailed the S&P 500 by 82.3 percentage points Trailed |
| 5Y | ATHE: down 81.7% S&P 500: up 67.3% −28.8% vs +10.8% a year | ATHE trailed the S&P 500 by 149.0 percentage points Trailed |
| 10Y | ATHE: down 90.5% S&P 500: up 311.8% −21.0% vs +15.2% a year | ATHE trailed the S&P 500 by 402.3 percentage points Trailed |
$10,000 invested in ATHE 10 years ago (Nov 4, 2016) would be worth about $953 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,184.
ATHE trailed the S&P 500 in all 7 periods.
| Period | ATHE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATHE: down 31.1% S&P 500: down 5.4% | ATHE trailed the S&P 500 by 25.7 percentage points Trailed |
| 3M | ATHE: down 49.2% S&P 500: down 4.8% | ATHE trailed the S&P 500 by 44.4 percentage points Trailed |
| YTD | ATHE: down 27.9% S&P 500: up 7.5% | ATHE trailed the S&P 500 by 35.4 percentage points Trailed |
| 1Y | ATHE: down 43.1% S&P 500: up 8.2% | ATHE trailed the S&P 500 by 51.3 percentage points Trailed |
| Long term | ||
| 3Y | ATHE: down 7.5% S&P 500: up 68.6% −2.6% vs +19.0% a year | ATHE trailed the S&P 500 by 76.1 percentage points Trailed |
| 5Y | ATHE: down 81.7% S&P 500: up 56.4% −28.8% vs +9.4% a year | ATHE trailed the S&P 500 by 138.1 percentage points Trailed |
| 10Y | ATHE: down 90.5% S&P 500: up 251.5% −21.0% vs +13.4% a year | ATHE trailed the S&P 500 by 342.0 percentage points Trailed |
$10,000 invested in ATHE 10 years ago (Nov 4, 2016) would be worth about $953 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,147.
All-time high
$765.00
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Sep 5, 2002.
Stock splits
2
Latest: 1-for-10 on . Share counts adjust after each split.
Both splits
- 1-for-10
- 1-for-6
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY23 (Dec 31, 2022) | Not reported | Not reported | Not reported |
| Q4 FY23 (Jun 30, 2023) | Not reported | Not reported | Not reported |
| Q2 FY24 (Dec 31, 2023) | Not reported | Not reported | Not reported |
| Q4 FY24 (Jun 30, 2024) | Not reported | Not reported | Not reported |
| Q2 FY25 (Dec 31, 2024) | Not reported | Not reported | Not reported |
| Q4 FY25 (Jun 30, 2025) | Not reported | Not reported | Not reported |
| Q2 FY26 (Dec 31, 2025) | Not reported | Not reported | Not reported |
| Q4 FY26 (Jun 30, 2026) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $3.53M | −$8.86M | Paused See the note under the price. |
| FY23 (Jun 30, 2023) | $2.59M | −$9.14M | −$2.26 |
| FY24 (Jun 30, 2024) | $2.68M | −$12.75M | −$2.10 |
| FY25 (Jun 30, 2025) | $5.03M | −$7.99M | −$0.75 |
| FY26 (Jun 30, 2026) | $2.49M | −$16.17M | −$0.92 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $25.79MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$133.70KAs of Jun 30, 2026
- Net cash$25.66MAs of Jun 30, 2026
- 14.52As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Alterity Therapeutics Ltd
Alterity’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Australia
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ATHE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ATHE stock FAQ
What is ATHE stock’s price today?
Alterity Therapeutics (ATHE) traded at $2.22 at the close on , down $0.22 (9.02%) from the previous close of $2.44. Over the past 52 weeks it has traded between $2.01 and $5.89.
If you invested $1,000 in ATHE 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ATHE on would be worth about $95 at the close on , a total return of −90.5%. The same $1,000 would be worth $183 if invested five years ago, $569 if invested one year ago, and $12 if invested 20 years ago. Past performance doesn’t predict future returns.
Does ATHE pay a dividend?
Alterity Therapeutics hasn’t paid a dividend in the last twelve months.
What is ATHE’s 52-week high and low?
Over the past 52 weeks ATHE has traded as low as $2.01 and as high as $5.89. At $2.22 at the close on , it is 62.3% below that high and 10.4% above the low.
What is ATHE’s all-time high?
ATHE’s highest closing price was $765.00 on , adjusted for stock splits. At $2.22 at the close on , it is 99.7% below that record.
Has ATHE stock ever split?
Yes, twice: 1-for-6 on ; 1-for-10 on .
How has ATHE stock performed?
Including dividends and measured to the close on , ATHE has returned −27.9% so far this year and −43.1% over the past year, and −81.7% over five years (−28.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Alterity Therapeutics in?
Alterity Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Australia.
What exchange does ATHE trade on?
Alterity Therapeutics trades on the Nasdaq under the ticker symbol ATHE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.